RxDoctor Payments Data

Angelita Palanca Capistrano, MD

Ophthalmology · Corona, CANPI 1578526521

Payments from drug & device makers

$20,135in general payments, 2019–2025

Across 260 payments — averaging $77.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$16K
  • AbbVie$1K
  • Bausch & Lomb Americas Inc.$646
  • Alcon$431
  • Aerie Pharmaceuticals, Inc.$303
  • Dompe US, Inc.$294
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$6,26931%
  • Speaking & faculty fees$7,08135%
  • Travel & lodging$1,4127%
  • Food & beverage$5,31426%
  • Education$390%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,135 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$248,128
Medicare patients
538
Services billed
2,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast41$52,735
Cyclosporine86$45,609
LumiganBimatoprost71$34,093
RestasisCyclosporine39$32,328
Alphagan PBrimonidine Tartrate25$12,745
Latanoprost684$8,783
Prednisolone Acetate333$8,681
Loteprednol Etabonate54$7,702
Brimonidine Tartrate113$5,981
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat269$5,661
Ketorolac Tromethamine239$3,692
Brinzolamide14$3,624
Travoprost12$2,955
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$2,784
Ofloxacin260$2,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$1,097$81,866148 claims
Bausch & Lomb Americas Inc.Xiidra$646$52,73541 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$243$7,70254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →